The phase II trial was done mainly to find out if maintenance therapy with DFMO after successfully finishing a standard, internationally recognized regimen for neuroblastoma would have any role in improving the EFS and OS of patients (primary and secondary endpoints of the study respectively) with high-risk neuroblastoma (metastatic/high proliferative index/MYCN+ve/relapsed/refractory disease). The gene discussed is MYCN; the disease is neuroblastoma.